AT252099T - Biarylcarboxamide - Google Patents
BiarylcarboxamideInfo
- Publication number
- AT252099T AT252099T AT01904770T AT01904770T AT252099T AT 252099 T AT252099 T AT 252099T AT 01904770 T AT01904770 T AT 01904770T AT 01904770 T AT01904770 T AT 01904770T AT 252099 T AT252099 T AT 252099T
- Authority
- AT
- Austria
- Prior art keywords
- biarylcarboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0000540A SE0000540D0 (en) | 2000-02-18 | 2000-02-18 | New compounds |
PCT/SE2001/000329 WO2001060821A1 (en) | 2000-02-18 | 2001-02-15 | Novel biarylcarboxamides |
Publications (1)
Publication Number | Publication Date |
---|---|
AT252099T true AT252099T (en) | 2003-11-15 |
Family
ID=20278508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01904770T AT252099T (en) | 2000-02-18 | 2001-02-15 | Biarylcarboxamide |
Country Status (33)
Country | Link |
---|---|
US (3) | US7001914B2 (en) |
EP (1) | EP1259508B1 (en) |
JP (1) | JP4084570B2 (en) |
KR (1) | KR100769394B1 (en) |
CN (1) | CN100345847C (en) |
AR (1) | AR029798A1 (en) |
AT (1) | AT252099T (en) |
AU (1) | AU782693B2 (en) |
BG (1) | BG106977A (en) |
BR (1) | BR0108456A (en) |
CA (1) | CA2397233A1 (en) |
CO (1) | CO5280046A1 (en) |
CZ (1) | CZ20022787A3 (en) |
DE (1) | DE60100996T2 (en) |
DK (1) | DK1259508T3 (en) |
EE (1) | EE05149B1 (en) |
ES (1) | ES2208556T3 (en) |
HK (1) | HK1050007A1 (en) |
HU (1) | HU0301069A3 (en) |
IL (1) | IL150544D0 (en) |
IS (1) | IS6492A (en) |
MX (1) | MXPA02007543A (en) |
NO (1) | NO20023917L (en) |
NZ (1) | NZ520094A (en) |
PL (1) | PL202044B1 (en) |
PT (1) | PT1259508E (en) |
RU (1) | RU2263114C2 (en) |
SE (1) | SE0000540D0 (en) |
SK (1) | SK11792002A3 (en) |
TR (1) | TR200400072T4 (en) |
UA (1) | UA73540C2 (en) |
WO (1) | WO2001060821A1 (en) |
ZA (1) | ZA200205479B (en) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0000540D0 (en) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
AU8287301A (en) * | 2000-08-18 | 2002-03-04 | Upjohn Co | Quinuclidine-substituted aryl compounds for treatment of disease |
EP1381603A2 (en) | 2000-08-18 | 2004-01-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
WO2002016356A2 (en) * | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
US6500840B2 (en) | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
AU8291001A (en) * | 2000-08-21 | 2002-03-04 | Upjohn Co | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
PE20021019A1 (en) * | 2001-04-19 | 2002-11-13 | Upjohn Co | Substituted azabicyclic groups |
AR036040A1 (en) | 2001-06-12 | 2004-08-04 | Upjohn Co | Quinuclidine-substituted multicyclic heteroaryl compounds and pharmaceutical compositions containing them |
AR036041A1 (en) | 2001-06-12 | 2004-08-04 | Upjohn Co | Quinuclidine-substituted heterocyclic aromatic compounds and pharmaceutical compositions containing them |
US6562816B2 (en) | 2001-08-24 | 2003-05-13 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease |
US20030105089A1 (en) * | 2001-09-12 | 2003-06-05 | Wishka Donn G. | Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease |
PL369895A1 (en) | 2001-10-02 | 2005-05-02 | Pharmacia & Upjohn Company | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
AU2002339810A1 (en) * | 2001-10-16 | 2003-04-28 | Astrazeneca Ab | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
MXPA04003986A (en) * | 2001-10-26 | 2004-07-23 | Upjohn Co | N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists. |
CA2466375A1 (en) * | 2001-11-08 | 2003-05-15 | Pharmacia & Upjohn Company | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease |
CA2466344A1 (en) | 2001-11-09 | 2003-05-22 | Pharmacia & Upjohn Company | Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands |
DE10156719A1 (en) | 2001-11-19 | 2003-05-28 | Bayer Ag | New N-(aza-bicycloalkyl)-benzo-heterocyclic carboxamides, useful as Alpha-7-nicotinic acetylcholine receptor ligands for e.g. improving attention, concentration, learning and/or memory performance |
DE10162375A1 (en) * | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclic N-aryl amides |
DE10164139A1 (en) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-heteroaryl carboxamides |
WO2003104227A1 (en) * | 2002-01-20 | 2003-12-18 | Bayer Healthcare Ag | 2-heteroaryl carboxamides |
US6852716B2 (en) | 2002-02-15 | 2005-02-08 | Pfizer Inc | Substituted-aryl compounds for treatment of disease |
WO2003070732A1 (en) * | 2002-02-19 | 2003-08-28 | Pharmacia & Upjohn Company | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
JP2005523287A (en) * | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Azabicyclo compounds for disease treatment |
DE10211415A1 (en) * | 2002-03-15 | 2003-09-25 | Bayer Ag | New azabicycloalkyl carboxylic acid N-biarylamides, are alpha-7-nicotinic acetylcholine receptor ligands useful for improving attention, concentration, learning and/or memory performance |
DE10211416A1 (en) | 2002-03-15 | 2003-09-25 | Bayer Ag | New azabicycloalkyl carboxylic acid N-arylamides, are alpha 7-nicotinic acetylcholine receptor ligands useful for improving attention, concentration, learning and/or memory performance |
US7176198B2 (en) | 2002-08-01 | 2007-02-13 | Pfizer Inc. | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
WO2004052348A2 (en) * | 2002-12-11 | 2004-06-24 | Pharmacia & Upjohn Company Llc | Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds |
AU2004206107A1 (en) * | 2003-01-22 | 2004-08-05 | Pharmacia & Upjohn Company Llc | Treatment of diseases with alpha-7 nach receptor full agonists |
GB0310867D0 (en) * | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
WO2005000250A2 (en) * | 2003-06-24 | 2005-01-06 | Johns Hopkins University | Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor |
DE10334724A1 (en) * | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-biaryl |
EP1699787A1 (en) * | 2003-12-22 | 2006-09-13 | AstraZeneca AB | Nicotinic acetylcholine receptor ligands |
AU2004303737A1 (en) * | 2003-12-22 | 2005-07-07 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
PE20060437A1 (en) | 2004-06-18 | 2006-06-08 | Novartis Ag | AZA-BICYCLONONE COMPOUNDS AS CHOLINERGIC BINDERS OF nAChR |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
US20090012127A1 (en) * | 2005-06-29 | 2009-01-08 | Astrazeneca Ab | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators |
GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
EP2520561B1 (en) | 2007-06-08 | 2016-02-10 | MannKind Corporation | IRE-1A Inhibitors |
TW200911808A (en) * | 2007-07-23 | 2009-03-16 | Astrazeneca Ab | Novel compounds |
TW201402116A (en) * | 2007-08-02 | 2014-01-16 | Targacept Inc | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
EP2488520B1 (en) | 2009-10-13 | 2015-09-02 | Merck Sharp & Dohme B.V. | Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor |
LT3029039T (en) | 2010-05-17 | 2018-02-26 | Forum Pharmaceuticals Inc. | Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate |
KR101928505B1 (en) | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | Pharmaceutical composition comprising pyridone derivatives |
KR101925971B1 (en) * | 2011-01-28 | 2018-12-06 | 에스케이바이오팜 주식회사 | Pharmaceutical composition comprising pyridone derivatives |
GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
JP6263469B2 (en) | 2011-07-15 | 2018-01-17 | ノバルティス アーゲー | Salt of azabicyclic di-aryl ether and method for producing the same or method for producing the precursor |
JO3115B1 (en) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | Pyridazinone Compounds and Their Use as DAAO Inhibitors |
AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
JP6478923B2 (en) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited | Piperidin-1-yl and azepine-1-yl carboxylate as muscarinic M4 receptor agonists |
EA029430B1 (en) | 2013-06-21 | 2018-03-30 | Такеда Фармасьютикл Компани Лимитед | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
FI20145054A (en) * | 2014-01-21 | 2015-07-22 | Tellabs Oy | Network element for a data transmission network |
TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
KR101623138B1 (en) | 2014-10-28 | 2016-05-20 | 한국원자력연구원 | Compositions and methods for the detection of amyloid plaques and the diagnosis of alzheimers disease |
GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1416872A (en) * | 1972-03-10 | 1975-12-10 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
FI791491A (en) * | 1979-05-10 | 1980-11-11 | Kopo Konepohja Oy | Traebitshugg |
FR2529548B1 (en) * | 1982-07-02 | 1985-04-19 | Delalande Sa | |
US4605652A (en) * | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
US4863919A (en) * | 1988-02-01 | 1989-09-05 | A. H. Robins Company, Incorporated | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes |
US5342845A (en) * | 1990-08-31 | 1994-08-30 | Nippon Shinyaku Company Limited | Indole derivatives and drugs |
JPH04247081A (en) * | 1991-02-01 | 1992-09-03 | Takeda Chem Ind Ltd | 5-membered heterocyclic acid amide |
SE9904176D0 (en) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
SE0000540D0 (en) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
FR2809731B1 (en) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | 1,4-diazabicyclo- [3.2.2] nonane-pheylisoxazole derivatives, their preparation and their therapeutic application |
FR2809730B1 (en) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | 1,4-diazabicyclo [3.2.2] nonanebenzoxazole, -benzothiazole and -benzimidazole derivatives, their preparation and their therapeutic application |
FR2809732B1 (en) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | DERIVATIVES OF 4 (-2-PHENYLTHIAZOL-5-yl) -1,4-DIAZABICYCLO- [3.2.2] NONANE, THEIR PREPARATION AND THEIR THERAPY APPLICATION |
TW593223B (en) | 2000-06-20 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
US6492385B2 (en) * | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
WO2002016356A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
AU8287301A (en) | 2000-08-18 | 2002-03-04 | Upjohn Co | Quinuclidine-substituted aryl compounds for treatment of disease |
EP1381603A2 (en) | 2000-08-18 | 2004-01-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
AU8291001A (en) | 2000-08-21 | 2002-03-04 | Upjohn Co | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
US6500840B2 (en) | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
DE10045112A1 (en) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Use of indole derivatives for the treatment of diseases of the central nervous system |
AU2051702A (en) | 2000-12-01 | 2002-06-11 | Neurosearch As | 3-substituted quinuclidines and their use as nicotinic agonists |
US20020086871A1 (en) | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
EP1699787A1 (en) * | 2003-12-22 | 2006-09-13 | AstraZeneca AB | Nicotinic acetylcholine receptor ligands |
US7396830B2 (en) * | 2005-10-04 | 2008-07-08 | Bristol-Myers Squibb Company | Piperazine amidines as antiviral agents |
-
2000
- 2000-02-18 SE SE0000540A patent/SE0000540D0/en unknown
-
2001
- 2001-02-12 AR ARP010100628A patent/AR029798A1/en unknown
- 2001-02-15 EP EP01904770A patent/EP1259508B1/en not_active Expired - Lifetime
- 2001-02-15 CZ CZ20022787A patent/CZ20022787A3/en unknown
- 2001-02-15 UA UA2002075475A patent/UA73540C2/en unknown
- 2001-02-15 WO PCT/SE2001/000329 patent/WO2001060821A1/en active IP Right Grant
- 2001-02-15 BR BR0108456-9A patent/BR0108456A/en not_active Application Discontinuation
- 2001-02-15 AU AU32594/01A patent/AU782693B2/en not_active Ceased
- 2001-02-15 PL PL357565A patent/PL202044B1/en not_active IP Right Cessation
- 2001-02-15 RU RU2002118302/04A patent/RU2263114C2/en active
- 2001-02-15 TR TR2004/00072T patent/TR200400072T4/en unknown
- 2001-02-15 DE DE60100996T patent/DE60100996T2/en not_active Expired - Fee Related
- 2001-02-15 PT PT01904770T patent/PT1259508E/en unknown
- 2001-02-15 EE EEP200200459A patent/EE05149B1/en not_active IP Right Cessation
- 2001-02-15 DK DK01904770T patent/DK1259508T3/en active
- 2001-02-15 SK SK1179-2002A patent/SK11792002A3/en unknown
- 2001-02-15 AT AT01904770T patent/AT252099T/en not_active IP Right Cessation
- 2001-02-15 KR KR1020027010731A patent/KR100769394B1/en not_active IP Right Cessation
- 2001-02-15 NZ NZ520094A patent/NZ520094A/en unknown
- 2001-02-15 CN CNB018049362A patent/CN100345847C/en not_active IP Right Cessation
- 2001-02-15 IL IL15054401A patent/IL150544D0/en unknown
- 2001-02-15 MX MXPA02007543A patent/MXPA02007543A/en active IP Right Grant
- 2001-02-15 JP JP2001560205A patent/JP4084570B2/en not_active Expired - Fee Related
- 2001-02-15 ES ES01904770T patent/ES2208556T3/en not_active Expired - Lifetime
- 2001-02-15 HU HU0301069A patent/HU0301069A3/en unknown
- 2001-02-15 CA CA002397233A patent/CA2397233A1/en not_active Abandoned
- 2001-02-16 CO CO01012482A patent/CO5280046A1/en not_active Application Discontinuation
-
2002
- 2002-04-15 US US10/123,856 patent/US7001914B2/en not_active Expired - Fee Related
- 2002-07-09 ZA ZA200205479A patent/ZA200205479B/en unknown
- 2002-08-02 BG BG106977A patent/BG106977A/en unknown
- 2002-08-08 IS IS6492A patent/IS6492A/en unknown
- 2002-08-16 NO NO20023917A patent/NO20023917L/en not_active Application Discontinuation
-
2003
- 2003-03-28 HK HK03102250A patent/HK1050007A1/en not_active IP Right Cessation
-
2006
- 2006-01-05 US US11/325,787 patent/US7214688B2/en not_active Expired - Fee Related
-
2007
- 2007-03-01 US US11/680,930 patent/US7491734B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60126142D1 (en) | Bioabsorbible wundauflage | |
DK1296587T3 (en) | Analytovervåger | |
DE60112603T2 (en) | Perkutane aortenklappe | |
DK1208782T3 (en) | Perkolationsindretning | |
DE60111771D1 (en) | Mikroklingeanordungsaufprallapplikator | |
DK1683491T3 (en) | Anastomoseforbindelsesapplikator | |
DK1294715T3 (en) | Quinazolinditosylatsaltforbindelser | |
DE60116715D1 (en) | Ablationskartierungskatheter | |
DK1335679T3 (en) | Tandbörstningssystem | |
DK1310136T3 (en) | Bredbåndsminiaturetransducer | |
DK1356188T3 (en) | Fluidblandingssystem | |
DK1439306T3 (en) | Bölgeenergiomformer | |
DK1298132T3 (en) | Hydropyridinderivatsyreadditionssalte | |
DK1158185T3 (en) | Hurtigfastgörelseselement | |
DK1330611T3 (en) | Teleskoparm | |
DE60024877D1 (en) | Elektrokauterisationskatheter | |
DE60132227D1 (en) | Tintenstrahlaufzeichungsmaterial | |
DE60133377D1 (en) | Dezellularized vasposis | |
DE60113289D1 (en) | Schergelzusammensetzungen | |
DK1345959T3 (en) | Membranscaffoldproteiner | |
DK1296647T3 (en) | Polymermicellepræparater | |
DK2312115T3 (en) | Rørindbygningsværktøj | |
DK1404939T3 (en) | Dørskinnesystem | |
DK1265560T3 (en) | Patellalejeimplantat | |
DE60119808D1 (en) | Fahrradantriebsnabe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1259508 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |